Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
267 CHF | -0.67% | +4.06% | +1.91% |
07:56am | Roche: EU approval for lung cancer | CF |
07:27am | Roche Secures EU Approval for Early-Stage Lung Cancer Treatment | MT |
Sales 2024 * | 60.39B 67.29B | Sales 2025 * | 63.83B 71.12B | Capitalization | 196B 219B |
---|---|---|---|---|---|
Net income 2024 * | 13.27B 14.79B | Net income 2025 * | 14.76B 16.45B | EV / Sales 2024 * | 3.48 x |
Net Debt 2024 * | 13.77B 15.34B | Net Debt 2025 * | 7.88B 8.78B | EV / Sales 2025 * | 3.2 x |
P/E ratio 2024 * |
14.3
x | P/E ratio 2025 * |
12.9
x | Employees | 103,605 |
Yield 2024 * |
4.04% | Yield 2025 * |
4.15% | Free-Float | 88.91% |
Latest transcript on Roche Holding AG
1 day | +1.28% | ||
1 week | +6.33% | ||
Current month | +6.33% | ||
1 month | +10.71% | ||
3 months | +6.33% | ||
6 months | -1.18% | ||
Current year | +2.83% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
Director/Board Member | 59 | - | |
Director/Board Member | 66 | 95-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.06% | 2 M€ | -.--% | - | |
2.06% | 2 M€ | +9.19% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 266.4 | -0.89% | 16 746 |
24-06-07 | 268.8 | +1.28% | 39,410 |
24-06-06 | 265.4 | +0.99% | 39,358 |
24-06-05 | 262.8 | +1.23% | 28,936 |
24-06-04 | 259.6 | +1.41% | 50,074 |
Delayed Quote Swiss Exchange, June 07, 2024 at 11:31 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
+11.88% | 216B | |
+5.90% | 164B | |
-0.73% | 162B | |
+1.53% | 123B |
- Stock Market
- Equities
- ROG Stock
- RO Stock